Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, Onglyza, Dapagliflozin, Farxiga, Glargine insulin, Metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 20
States / cities: Anaheim, California • Los Angeles, California • Miami, Florida + 15 more

Conditions: Gastroesophageal Reflux Disease
Interventions: Lansoprazole microgranules suspension, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 1 Month to 11 Months
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 9
States / cities: Tampa, Florida • Park Ridge, Illinois • Shreveport, Louisiana + 6 more

Conditions: Rectal Cancer, Surgery, Patient Activation, Low Anterior Resection, Low Anterior Resection Syndrome
Interventions: Patient Activation Booklet and nursing support for patients with LARS; Other
Lead sponsor: Jewish General Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza
Interventions: CR6261 2 mg/kg, CR6261 5 mg/kg, CR6261 15 mg/kg, CR6261 30 mg/kg, CR6261 50 mg/kg, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Scar Prevention
Interventions: EXC 001, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Chicago, Illinois • St Louis, Missouri

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 85
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • North Little Rock, Arkansas + 67 more

Conditions: Inflammatory Bowel Disease, Intestinal Fistula
Interventions: AST-120; Drug
Lead sponsor: Ocera Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 25
States / cities: Anaheim, California • San Carlos, California • Winter Park, Florida + 20 more

Conditions: Focal Seizure, Epilepsy, Focal Epilepsy
Interventions: RAP-219, Placebo; Drug · Other
Lead sponsor: Rapport Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Huntsville, Alabama • Bentonville, Arkansas • Colorado Springs, Colorado + 9 more

Conditions: Asthma
Interventions: Placebo, MEDI9929 70 mg, MEDI9929 210 mg, MEDI9929 280 mg; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 18
States / cities: Los Angeles, California • Miami, Florida • Oviedo, Florida + 12 more

Conditions: Stress Disorder, Post Traumatic
Interventions: EEG-based personalized TMS, Sham Comparator; Device
Lead sponsor: Wave Neuroscience; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Dayton, Ohio • Pickerington, Ohio

Conditions: Radiation Dermatitis
Interventions: Gentlewaves Select™ handheld high energy LED array, Radiation; Device · Radiation
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Orange, California

Conditions: Gastroparesis
Interventions: Gastric endoscopic peroral pyloromyotomy, Esophago-gastro-duodenoscopy; Procedure
Lead sponsor: Institute for Clinical and Experimental Medicine; Government
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Knee Osteoarthritis (Knee OA)
Interventions: genicular artery embolization, Corticosteroid Injection; Device · Drug
Lead sponsor: North American Science Associates Ltd.; Network
Eligibility: 40 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
Interventions: ACP-211, Placebo; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 28
States / cities: Birmingham, Alabama • Chino, California • Glendale, California + 24 more

Conditions: Cataract
Interventions: enVista MX60E, enVista MX60EF; Device
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 22 Years and older
Enrollment: 501 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 23
States / cities: Fayetteville, Arkansas • Garden Grove, California • Northridge, California + 19 more

Conditions: Endometrial Neoplasms
Interventions: olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years · Female only
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 50
States / cities: Tucson, Arizona • Concord, California • La Jolla, California + 45 more

Conditions: Serious Gram-negative Infections
Interventions: Intravenous infusions of WCK 5222, Placebo; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Congestive Heart Failure, Diastolic Heart Failure, Systolic Heart Failure
Interventions: Expanded technology disease management, Telephonic disease management; Other
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts • Framingham, Massachusetts

Conditions: Hypertension, Stress, Psychological, Blood Pressure
Interventions: Prazosin, Placebo; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Older Adults, Mental Health, Depression, Loneliness, Social Isolation, Suicide Ideations, Social Functioning, Quality of Life, Thwarted Belongingness, Perceived Burdensomeness, Help-Seeking Behavior, Suicide Risk
Interventions: standardized and manualized warm calls from providers trained in the BE training, standardized and manualized warm calls from providers trained in the BE training + ASIST training; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 55 Years and older
Enrollment: 671 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cancer
Interventions: PS-OT, Usual care; Behavioral · Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo, fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 913 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 57
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 54 more

Conditions: Asthma
Interventions: APG777, Placebo; Drug
Lead sponsor: Apogee Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: La Jolla, California • Long Beach, California • San Jose, California + 6 more

Conditions: Working Memory
Interventions: Transcranial alternating current stimulation (tACS); Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux

Impact of a Patient-Centered Program for Low Anterior Resection Syndrome a Multicenter Randomized Controlled Trial

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma

EEG-based Personalized Transcranial Magnetic Stimulation (eTMS) to Treat Post-Traumatic Stress Disorder

LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis

Endoscopic Pyloromyotomy for Refractory Gastroparesis

Randomized Controlled Study Evaluating Genicular Artery Embolization Against Intra-Articular Corticosteroid Knee Injection for Osteoarthritic Knee Pain

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers

A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure

Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress

The BE WITH Project: A Partially Nested Randomized Control Trial (PN-RCT)

Reducing Disability in Older Adult Cancer Survivors

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma

Traveling-wave Transcranial Electric Stimulation